(DIS)AGREE: (DIS)AGreement of Relatives Regarding Ethical End-of-life Decisions in ICU.

Sponsor
Société Française d'Anesthésie et de Réanimation (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05768906
Collaborator
(none)
400
14

Study Details

Study Description

Brief Summary

In the ICU, the vast majority of patients die following a life-sustaining therapies (LST) limitation decision. Most often, the patient is not able to express himself and has not made his wishes known beforehand, for example in the form of advance directives. The "relatives" are then the only recourse to state the patient's wishes, without any guarantee that they are aware of them. In France, the final decision is made by the physician (or the medical team) who is responsible for it. In this context, disagreements and even real legal conflicts on LST limitation decisions between relatives and physicians seem to be more and more frequent. To our knowledge, few data exist on the frequency of these disagreements over LST limitation decisions.

The main objective of this study is to evaluate the frequency of disagreements between relatives and physicians over LST limitation decisions in adult intensive care.

Condition or Disease Intervention/Treatment Phase
  • Other: observational

Detailed Description

Context In the ICU, the vast majority of patients die following a life-sustaining therapies (LST) limitation decision. Most often, the patient is not able to express himself and has not made his wishes known beforehand, for example in the form of advance directives. The "relatives" are then the only recourse to state the patient's wishes, without any guarantee that they are aware of them. In France, the final decision is made by the physician (or the medical team) who is responsible for it. In this context, disagreements and even real legal conflicts on LST limitation decisions between relatives and physicians seem to be more and more frequent. To our knowledge, few data exist on the frequency of these disagreements over LST limitation decisions.

Purpose The main objective of this study is to evaluate the frequency of disagreements between relatives and physicians over LST limitation decisions in adult intensive care.

The secondary objectives are:
  • To assess the level of agreement/disagreement between family members and physicians regarding LST limitation decisions

  • To assess the proportion of disagreements experienced as conflictual

  • To assess the impact of the disagreement on the LST limitation decision (implementation of the decision, time between the decision and its implementation, length of hospitalization...)

  • To describe possible factors that contribute to disagreement and conflict

  • To describe national LST limitation decision-making practices.

Study Design

Study Type:
Observational
Anticipated Enrollment :
400 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
(DIS)AGreement of Relatives Regarding Ethical End-of-life Decisions in ICU.
Anticipated Study Start Date :
Mar 15, 2023
Anticipated Primary Completion Date :
Mar 15, 2024
Anticipated Study Completion Date :
May 15, 2024

Arms and Interventions

Arm Intervention/Treatment
Life-sustaining therapies limitation decision situations - observation only

For each participating center, consecutive inclusion of the first 10 life-sustaining therapies limitation decision situations from the study start date over a maximum of 12 months. Data collection for these patients especialy information concerning disagreements and even real legal conflicts on life-sustaining therapies limitation decisions between relatives and physicians.

Other: observational
Observation of disagreements and even real legal conflicts on life-sustaining therapies limitation decisions between relatives and physicians

Outcome Measures

Primary Outcome Measures

  1. Frequency of disagreements - Using linkert scale [At the latest by may 31, 2024]

    Evaluate the frequency of disagreements between relatives and physicians over LST limitation decisions in adult intensive care. A linkert scale will be used to cote the disagreements and will be completed by the investigator.

Secondary Outcome Measures

  1. Level of agreement/disagreement - Using linkert scale [At the latest by may 31, 2024]

    To assess the level of agreement/disagreement between family members and physicians regarding life-sustaining therapies limitation decisions. A linkert scale will be used to cote the level of agreement/disagreement and will be completed by the investigator. Data will be expressed as numbers and percentages or medians and interquartile ranges. The data will be compared by the appropriate non-parametric tests.

  2. Proportion of disagreements experienced as conflictual - Using linkert scale [At the latest by may 31, 2024]

    To assess the proportion of disagreements experienced as conflictual. A linkert scale will be used to cote the level of Proportion of disagreements experienced as conflictual and will be completed by the investigator. Data will be expressed as numbers and percentages or medians and interquartile ranges. The data will be compared by the appropriate non-parametric tests.

  3. Impact of the disagreement on the life-sustaining therapies limitation decision. Evaluation by questionnary. [At the latest by may 31, 2024]

    To assess the impact of the disagreement on the life-sustaining therapies limitation decision. Questionnary will be completed by the investigator.Data will be expressed as numbers and percentages or medians and interquartile ranges. The data will be compared by the appropriate non-parametric tests.

  4. Factors identification [At the latest by may 31, 2024]

    To describe possible factors that contribute to disagreement and conflict. Data will be expressed as numbers and percentages or medians and interquartile ranges. The data will be compared by the appropriate non-parametric tests

  5. Description of national practices - Aggregation of responses from all sites [At the latest by may 31, 2024]

    To describe national life-sustaining therapies limitation decision-making practices. Aggregation of responses to questions of the CRF from all sites Data will be expressed as numbers and percentages or medians and interquartile ranges. The data will be compared by the appropriate non-parametric tests.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Consecutive inclusion of all situations in which a life-sustaining therapies limitation decision was made

  • Patients hospitalized in a French intensive care unit

  • Age of the patient ≥ 18 years

  • If relatives are present, age of at least one of the relatives ≥ 18 years NB: situations of "non-re-admission" decisions in intensive care are not taken into account in the inclusion criteria.

Exclusion Criteria:
  • Minor patient

  • Patient under guardianship

  • Conscious patient, able to express himself/herself and able to decide jointly with the medical team

  • Patient for whom a life-sustaining therapies limitation decision was already made prior to inclusion

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Société Française d'Anesthésie et de Réanimation

Investigators

  • Study Chair: Mikhael Giabicani, MD, Hôpital Beaujon - 100 boulevard du Général Leclerc - 92110 Clichy

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Société Française d'Anesthésie et de Réanimation
ClinicalTrials.gov Identifier:
NCT05768906
Other Study ID Numbers:
  • 2022-02
First Posted:
Mar 15, 2023
Last Update Posted:
Mar 15, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 15, 2023